161 related articles for article (PubMed ID: 9489331)
1. [Preliminary results on the use of scintigraphy with radiolabelled octreotide as diagnostic method in neuroendocrine and nonendocrine neoplasms of the lung].
Oliaro A; Filosso PL; Bellò M; Casadio C; Muni A; Angusti T; Masaneo I; Bisi G; Maggi G
Minerva Chir; 1997 Nov; 52(11):1335-8. PubMed ID: 9489331
[TBL] [Abstract][Full Text] [Related]
2. Use of 111In-DTPA-octreotide scintigraphy in the diagnosis of neuroendocrine and non-neuroendocrine tumors of the lung. Preliminary results.
Oliaro A; Filosso PL; Bello M; Casadio C; Angusti T; Masaneo I; Maggi G; Bisi G
J Cardiovasc Surg (Torino); 1997 Jun; 38(3):313-5. PubMed ID: 9219485
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine carcinomas of the lung and role of 111In-DTPA-octreotide scintigraphy: preliminary results.
Oliaro A; Filosso PL; Bello M; Casadio C; Muni A; Greco B; Bertuccio G; Bisi G; Maggi G
J Cardiovasc Surg (Torino); 1996 Dec; 37(6):653-6. PubMed ID: 9016988
[TBL] [Abstract][Full Text] [Related]
4. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
Shi W; Johnston CF; Buchanan KD; Ferguson WR; Laird JD; Crothers JG; McIlrath EM
QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor imaging.
Kwekkeboom DJ; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):84-91. PubMed ID: 11965603
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan).
Olsen JO; Pozderac RV; Hinkle G; Hill T; O'Dorisio TM; Schirmer WJ; Ellison EC; O'Dorisio MS
Semin Nucl Med; 1995 Jul; 25(3):251-61. PubMed ID: 7570044
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.
Krenning EP; Kwekkeboom DJ; Bakker WH; Breeman WA; Kooij PP; Oei HY; van Hagen M; Postema PT; de Jong M; Reubi JC
Eur J Nucl Med; 1993 Aug; 20(8):716-31. PubMed ID: 8404961
[TBL] [Abstract][Full Text] [Related]
8. [Role of somatostatin analogs in the treatment of neuroendocrine tumours].
Cuccurullo V; Cascini GL; Rambaldi PF; Mansi L
Minerva Endocrinol; 2001 Sep; 26(3):135-43. PubMed ID: 11753236
[TBL] [Abstract][Full Text] [Related]
9. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
Wiedenmann B; Bäder HM; Scherubl H; Fett U; Zimmer T; Hamm B; Koppenhagen K; Riecken EO
Semin Oncol; 1994 Oct; 21(5 Suppl 13):29-32. PubMed ID: 7992077
[No Abstract] [Full Text] [Related]
10. Localization of gastroenteropancreatic neuroendocrine tumors with 111indium-pentetreotide scintigraphy.
Pauwels S; Leners N; Fiasse R; Jamar F
Semin Oncol; 1994 Oct; 21(5 Suppl 13):15-20. PubMed ID: 7992075
[No Abstract] [Full Text] [Related]
11. Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview.
Kwekkeboom DJ; Krenning EP
Eur Radiol; 1997; 7(7):1103-9. PubMed ID: 9265684
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
Kwekkeboom DJ; Lamberts SW; Habbema JD; Krenning EP
J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphy.
Bombardieri E; Crippa F; Cataldo I; Chiti A; Seregni E; Soresi E; Boffi R; Invernizzi G; Buraggi GL
Eur J Cancer; 1995; 31A(2):184-8. PubMed ID: 7718323
[TBL] [Abstract][Full Text] [Related]
14. 111In-DTPA-D-Phe-1-octreotide scintigraphy of small cell lung cancer.
Bombardieri E; Chiti A; Crippa F; Seregni E; Cataldo I; Maffioli L; Soresi E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):104-7. PubMed ID: 9002763
[TBL] [Abstract][Full Text] [Related]
15. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas].
Banzo J; Abós MD; Prats E; García F; Razola P
Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088
[No Abstract] [Full Text] [Related]
16. 111In-octreotide scintigraphy in small cell lung cancer.
Semprebene A; Ferraironi A; Franciotti G; Venturo I; Giunta S; Lopez M; Maini CL
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):108-10. PubMed ID: 9002764
[TBL] [Abstract][Full Text] [Related]
17. Tc-99m sestamibi and In-111 DTPA octreotide uptake in breast carcinoma with neurendocrine differentiation.
Rubini G; D'Eredità G
Clin Nucl Med; 2000 Jun; 25(6):482-3. PubMed ID: 10836705
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor imaging in patients with neuroendocrine tumors: preoperative and postoperative scintigraphy and intraoperative use of a scintillation detector.
Ahlman H; Tisell LE; Wängberg B; Nilsson O; Forssell-Aronsson E; Fjälling M
Semin Oncol; 1994 Oct; 21(5 Suppl 13):21-8. PubMed ID: 7992076
[No Abstract] [Full Text] [Related]
19. Somatostatin receptor imaging in small cell lung cancer.
Berenger N; Moretti JL; Boaziz C; Vigneron N; Morere JF; Breau JL
Eur J Cancer; 1996 Jul; 32A(8):1429-31. PubMed ID: 8869110
[TBL] [Abstract][Full Text] [Related]
20. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide.
Forssell-Aronsson E; Fjälling M; Nilsson O; Tisell LE; Wängberg B; Ahlman H
J Nucl Med; 1995 Jan; 36(1):7-12. PubMed ID: 7799086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
